Canopus BioPharma to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Canopus BioPharma, Inc. (OTCPK: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today that it will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York on November 5-7, 2007.
Patrick Prendergast, Chief Executive Officer of Canopus BioPharma, will present on November 7 at 8:50 AM Eastern. Also in attendance for the Company will be Len Rothstein, President, and Leo Prendergast, Chief Operating Officer. For those unable to attend the event, the Canopus BioPharma presentation is being webcast and can be accessed live or in replay format for a limited time at the following link: http://wsw.com/webcast/rrshq12/cbia.pk
Presentations by more than 350 emerging growth biotechnology companies are expected at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference that rapidly has become the premier event on the Life Sciences calendar. Companies will share their accomplishments on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. The event will unite companies with institutional investors, venture capitalists, senior corporate executives and experts from the scientific and medical communities. The Conference will include company presentations, breakout sessions, and one-on-one meetings with presenting companies.
About Rodman & Renshaw:
Rodman & Renshaw is a full service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies, along with research and sales and trading services to institutional investor clients that focus on such companies. Through its AcumenBioFin TM division, Rodman is a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
About Canopus BioPharma, Inc.:
Canopus BioPharma, Inc. (OTCPK: CBIA) is dedicated to providing the safest, most cost effective and efficacious pharmaceutical products and assay methods to patients suffering from infectious disease, bio-terrorism, cancer, and addiction. With innovative science, proven research and development leadership, and superior products and compounds, Canopus BioPharma has since 2001 been committed to becoming a market trend setter in the new era of healthcare, which is focused on providing affordable therapeutic and diagnostic benefits and pharmaceutical excellence to patients and healthcare professionals worldwide. In addition, the Company is a world leader in the development of novel camelid antibody products to provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers, particularly for food chain protection applications. Canopus maintains staff in Australia, South Africa, Ireland, Panama and the USA. Additional information on the Company is available at www.canopusbiopharma.com.
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. In particular, the Company may not be successful in its efforts commercialize or attain acceptable clinical results for its products. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts and research and development programs, uncertainties as a result of research and development, consumer and industry acceptance, litigation and/or court proceedings, regulatory risks including approval of Food and Drug Administration filings, the ability to achieve and maintain revenues and profitability in the Company’s business lines, and other factors discussed in the Company’s filings with the Securities and Exchange Commission.